{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-100891","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.748687+00:00","generated_at":"2026-05-17T22:42:17.517995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OPKO Health Q2 revenue $156.8M down 14% YoY; net loss includes $91.7M convertible note charge","bullets":["Consolidated revenue $156.8M vs $182.2M in Q2 2024; net loss $148.4M ($0.19/share) vs $10.3M loss ($0.01) prior year, including $91.7M non-recurring convertible note expense.","Diagnostics revenue $101.1M (-22% YoY) on lower clinical test volume from BioReference asset sale; operating loss improved to $18.2M from $26.6M.","Pharmaceuticals revenue $40.7M (flat); operating loss $28.7M vs $24.8M, driven by higher R&D for pipeline programs.","Board authorized additional $100M share repurchase, total capacity $200M; $58.5M repurchased through June 30.","FDA approved 4Kscore Test without DRE; Merck Phase 1 EBV vaccine and multiple pipeline programs advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-100891","json":"https://secwatch.observer/filing/0000950170-25-100891.json","markdown":"https://secwatch.observer/filing/0000950170-25-100891.md","text":"https://secwatch.observer/filing/0000950170-25-100891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000095017025100891/0000950170-25-100891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000095017025100891/opk-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:42:17.517995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}